Short Squeeze Setup — velZ +0.83 · age 29w×0.97 · 14.33%
Founder-Led — founder/CEO led
About BioCryst Pharmaceuticals Inc
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. Read full Trend Edge analysis →
Sector: Healthcare
Industry: Drug Manufacturers-Specialty & Generic
Exchange: NASDAQ
IPO Date: March 3, 1994
Headquarters: 4505 Emperor Boulevard, Durham, NC, United States, 27703
Founder-Led: Yes — Yarlagadda S. Babu (Chief Discovery Officer)
Key Metrics
Current Price
$9.83
Market Cap
$2.47B
Float
222.4M
Shares Outstanding
255.5M
P/E (Forward)
29.59
Price/Sales (TTM)
2.62
vs. Analyst Target
+111.8% to analyst PT
Profit Margin
-40.90%
Operating Margin (TTM)
45.12%
Revenue (TTM)
$941M
Earnings Growth (YoY)
1400.00%
Dividend Rate
None
Analyst Target Price
$20.82 (12 analysts)
Financial History
Annual Revenue & Earnings History
Year
Revenue
Net Income
Gross Profit
EBITDA
2020
$17.8M
-$183M
$16.1M
-$168M
2021
$157M
-$184M
$150M
-$122M
2022
$271M
-$247M
$264M
-$144M
2023
$331M
-$227M
$327M
-$116M
2024
$451M
-$88.9M
$438M
$12.8M
2025
$875M
$264M
$856M
$348M
Recent Quarterly Revenue & Net Income
Quarter
Revenue
Net Income
Sep 2025
$159M
$12.9M
Dec 2025
$407M
$246M
Mar 2026
$156M
-$722M
Jun 2026
$218M
$78.4M
Ownership & Float
Insider Ownership
1.2%
Institutional Ownership
105.3%
Short Float
14.8%
% of All Funds Holding
3.59%
Number of Funds Holding
316
Current Moving Averages
Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.
Timeframe
SMA
Value
Trend Context
Weekly
10-Week SMA
$9.63
Near-term / short-term trend
Weekly
40-Week SMA
$8.52
Medium-term trend
Weekly
80-Week SMA
$8.44
Cyclical trend (business cycle)
Weekly
200-Week SMA
$7.90
Secular trend (multi-year)
Monthly
10-Month SMA
$8.67
Near-term monthly trend
Monthly
20-Month SMA
$8.53
Medium-term monthly trend
Monthly
40-Month SMA
$7.61
Secular monthly trend
Volume Shelves — Support & Resistance
Trend Edge identifies volume shelves: price zones where historically elevated trading volume
creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative
volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.
Price Level
Type
Volume Ratio
Age
$8.80
support
1.20x
1 months ago
$10.70
resistance
1.15x
13 months ago
Historical Earnings Reactions (127 events)
Timeframe
Avg Return
Median
Win Rate
Best
Worst
Gap
0.84%
0.00%
47.24%
42.53%
-5.90%
1 Day
0.73%
0.13%
51.18%
14.28%
-11.86%
1 Week
1.37%
-0.78%
47.24%
40.83%
-42.30%
2 Weeks
2.68%
0.97%
53.54%
51.72%
-54.67%
1 Month
5.72%
0.62%
52.38%
134.50%
-54.16%
Next earnings: October 24, 2026 (59 days away)
Seasonality & Day-of-Week Patterns
Monthly Seasonality
Month
Avg Return
Win Rate
Samples
Jan
2.5%
56.3%
32
Feb
0.1%
53.1%
32
Mar
1.7%
37.5%
32
Apr
4.6%
54.5%
33
May
6.1%
54.5%
33
Jun
3.0%
60.6%
33
Jul
10.6%
54.5%
33
Aug
10.0%
59.4%
32
Sep
-4.9%
34.4%
32
Oct
-4.7%
50.0%
32
Nov
3.7%
46.9%
32
Dec
0.5%
50.0%
32
Day-of-Week Tendencies
Day
Avg Return
Win Rate
Samples
Monday
0.26%
47.3%
1537
Tuesday
-0.04%
43.9%
1678
Wednesday
0.24%
47.3%
1676
Thursday
-0.01%
44.1%
1644
Friday
0.27%
45.1%
1636
Top Institutional Holders
Institutional holder breakdown coming soon.
Total institutional ownership: 105.3%
Insider Transactions — Smart Summary
Total insider ownership: 1.2%
Founder-led management: Yarlagadda S. Babu (Chief Discovery Officer)
Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for BioCryst Pharmaceuticals Inc
(BCRX) powered by Claude Opus — Anthropic's most capable AI model.
The analysis covers five layers:
technical analysis (near-term, medium-term, cyclical, and secular trend, momentum,
volume shelf support and resistance, breakout and breakdown signals),
qualitative analysis (business model, competitive moat, sector dynamics),
insider sentiment (buy and sell signals from executive and director transactions),
share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and
fundamental analysis (valuation, revenue growth, profit margin, earnings quality).
AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit,
stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward.
Whether you are building a long position, initiating a short, or looking for a reversal setup,
AI Consult identifies the highest-probability signal from the current trend.